Lanean...

P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sylvan, S Eketorp, Lundin, J, Ipek, M, Palma, M, Karlsson, C, Hansson, L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2014
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4072199/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2051-1426-2-S2-P18
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!